Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,235 Mln
Revenue (TTM)
$605 Mln
Net Profit (TTM)
$0 Mln
ROE
0.5 %
ROCE
-- %
P/E Ratio
19.4
P/B Ratio
8.3
Industry P/E
--
EV/EBITDA
26.5
Div. Yield
0 %
Debt to Equity
1
Book Value
$11.6
EPS
$4.6
Face value
--
Shares outstanding
34,302,451
CFO
$-223.45 Mln
EBITDA
$-179.01 Mln
Net Profit
$-236.41 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TransMedics Group (TMDX)
| -17.2 | -30.7 | -17.2 | 47.5 | 10.0 | 20.2 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
TransMedics Group (TMDX)
| 95.1 | -20.9 | 27.9 | 222.1 | -3.7 | 4.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
TransMedics Group (TMDX)
|
100.7 | 3,235.1 | 605.5 | 190.3 | 20.0 | 54.2 | 19.4 | 8.3 |
| 7.9 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 25.8 | 3,989.0 | 2,719.5 | 47.0 | 8.4 | 1.6 | 86.6 | 1.3 | |
| 112.8 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a... portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Address: 200 Minuteman Road, Andover, MA, United States, 01810 Read more
Founder, President, CEO & Director
Dr. Waleed H. Hassanein M.D.
Founder, President, CEO & Director
Dr. Waleed H. Hassanein M.D.
Headquarters
Andover, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of TransMedics Group Inc (TMDX) is $100.70 (NASDAQ) as of 02-Apr-2026 16:01 EDT. TransMedics Group Inc (TMDX) has given a return of 9.96% in the last 3 years.
The P/E ratio of TransMedics Group Inc (TMDX) is 19.37 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
26.16
|
10.52
|
|
2024
|
61.91
|
9.60
|
|
2023
|
-107.79
|
19.66
|
|
2022
|
-54.53
|
10.54
|
|
2021
|
-12.03
|
7.84
|
The 52-week high and low of TransMedics Group Inc (TMDX) are Rs 156.00 and Rs 62.23 as of 03-Apr-2026.
TransMedics Group Inc (TMDX) has a market capitalisation of $ 3,235 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in TransMedics Group Inc (TMDX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.30
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.